A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis
Kian Jalaleddini, Mike Edgeworth, Shannon R. McCurdy(Hospital of the University of Pennsylvania), Ferhan Qureshi, David Weinstein, Sreeranjani Menon, Bari Talente(National Multiple Sclerosis Society), Ati Ghoreyshi, Miyuru Amarapala, Robert A Bermel(Cleveland Clinic), Maital Rasmussen, Kesshi Jordan
Cited by 2
Related Papers
How patients with multiple sclerosis acquire disability
|Brain|2022|532
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
|Journal of Clinical Oncology|2017|325
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
|Blood|2015|299